GSK struck multiple deals this week to bulk up its pipeline: a global license for two Frontier Biotechnologies siRNA programs worth up to ~$1 billion, and a $950 million cash acquisition of 35Pharma, which brings a phase II‑ready pulmonary hypertension candidate. The Frontier deal gives GSK rights to oligonucleotide immunology assets, including an IND‑stage program, while the 35Pharma purchase adds HS‑235 for PAH and strengthens cardiopulmonary capabilities. Company executives framed the transactions as strategic platform and therapeutic expansions. The twin moves underscore big pharma’s continued appetite for external innovation—oligonucleotides and small biologics—and signal increased competition in cardiopulmonary and immunology franchises.